20 (AIDX) Non-Current Deffered Revenue (2024 - 2026)

20 (AIDX) posted Non-Current Deffered Revenue of $37055.0 for Q1 2026, down 11.39% on a QoQ basis from $41816.0 in Q4 2025.

20 (AIDX) Non-Current Deffered Revenue (2024 - 2026) Analysis & Trends

20's Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $37055.0 for Q1 2026.

Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $37055.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37055.0 (changed N/A YoY) and the FY2025 annual result came in at $41816.0, down 16.37% from the prior year.
Non-Current Deffered Revenue was $37055.0 for Q1 2026 at 20, down from $41816.0 in the prior quarter.
Across five years, Non-Current Deffered Revenue topped out at $50000.0 in Q4 2024 and bottomed at $37055.0 in Q1 2026.
A 3-year average of $42957.0 and a median of $41816.0 in 2025 frame the typical range for Non-Current Deffered Revenue.
Peak annual rise in Non-Current Deffered Revenue reached 16.37% in 2025, while the deepest fall reached 16.37% in 2025.
20's Non-Current Deffered Revenue stood at $50000.0 in 2024, then retreated by 16.37% to $41816.0 in 2025, then decreased by 11.39% to $37055.0 in 2026.
Business Quant data shows AIDX's Non-Current Deffered Revenue at $37055.0 in Q1 2026, $41816.0 in Q4 2025, and $50000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	-
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	-
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	-
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	-
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	-
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	512.79 Mn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	-
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	-
10	20	3.91 Mn	-313,912.28	62,884.00	37,055.00

Download Data